240 related articles for article (PubMed ID: 9563704)
1. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
Schwartz E; Raveh D
Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
[TBL] [Abstract][Full Text] [Related]
2. [The value of screening serology in anti-hepatitis A vaccination of travelers].
Landry P; Darioli R
Schweiz Med Wochenschr; 1998 Apr; 128(15):581-5. PubMed ID: 9606799
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
Van Doorslaer E; Tormans G; Van Damme P
J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis A antibodies in attenders of London Travel Clinics: cost-benefit of screening prior to hepatitis A immunisation.
Zuckerman JN; Powell L
J Med Virol; 1994 Dec; 44(4):393-4. PubMed ID: 7897370
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy.
Moschen ME; Floreani A; Zamparo E; Baldo V; Majori S; Gasparini V; Trivello R
Eur J Epidemiol; 1997 Dec; 13(8):875-8. PubMed ID: 9476815
[TBL] [Abstract][Full Text] [Related]
6. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
Reintjes R; Bosman A; de Zwart O
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
[TBL] [Abstract][Full Text] [Related]
7. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination.
Saab S; Martin P; Yee HF
Am J Med; 2000 Aug; 109(3):241-4. PubMed ID: 10974188
[No Abstract] [Full Text] [Related]
8. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries.
Bayas JM; González A; Vilella A; San-Martín M; Bertran MJ; Adell C
Epidemiol Infect; 2001 Oct; 127(2):347-51. PubMed ID: 11693513
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine.
Dhawan PS; Shah SS; Alvares JF; Kher A; Shankaran ; Kandoth PW; Sheth PN; Kamath H; Kamath A; Koppikar GV; Kalro RH
Indian J Gastroenterol; 1998 Jan; 17(1):16-8. PubMed ID: 9465507
[TBL] [Abstract][Full Text] [Related]
11. Routine testing for IgG antibodies against hepatitis A virus in Israel.
Samuels N
BMC Public Health; 2005 Jun; 5():60. PubMed ID: 15935104
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of hepatitis A prevention in France.
Severo CA; Fagnani F; Lafuma A
Pharmacoeconomics; 1995 Jul; 8(1):46-61. PubMed ID: 10155601
[TBL] [Abstract][Full Text] [Related]
13. Changes to country-specific hepatitis A travel vaccination recommendation for UK travellers in 2017-responding to a vaccine shortage in the national context.
Petersen J; Freedman J; Ford L; Gawthrop M; Simons H; Edelstein M; Plunkett J; Balogun K; Mandal S; Patel D
Public Health; 2019 Mar; 168():150-156. PubMed ID: 30442468
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of antibodies against hepatitis A (anti-HAV) in Singapore: the NFDD experience.
Fock KM; Tay HH; Phua KB; Guan R; Chia SC; Chong R; Chee AE; Chew CN
Singapore Med J; 1995 Feb; 36(1):26-7. PubMed ID: 7570129
[TBL] [Abstract][Full Text] [Related]
15. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations.
Ceyhan M; Yildirim I; Kurt N; Uysal G; Dikici B; Ecevit C; Aydogan A; Koc A; Yasa O; Köseoğlu M; Onal K; Hacimustafaoglu M; Celebi S
J Viral Hepat; 2008 Oct; 15 Suppl 2():69-72. PubMed ID: 18837839
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation of vaccination against hepatitis A for frequent travellers.
Fenn P; McGuire A; Gray A
J Infect; 1998 Jan; 36(1):17-22. PubMed ID: 9515663
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective analysis of hepatitis A prevention in Ireland.
Rajan E; Shattock AG; Fielding JF
Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
[TBL] [Abstract][Full Text] [Related]
18. Screening travelers for hepatitis A antibodies: an observational cost-comparison study of vaccine use.
Lee KK; Beyer-Blodget J
West J Med; 2000 Nov; 173(5):325-9. PubMed ID: 11069868
[TBL] [Abstract][Full Text] [Related]
19. HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries.
Pedersini R; Marano C; De Moerlooze L; Chen L; Vietri J
Travel Med Infect Dis; 2016; 14(3):221-32. PubMed ID: 27000975
[TBL] [Abstract][Full Text] [Related]
20. Anti-HAV seroprevalence in German travellers and hepatitis A vaccination in immune subjects.
Bienzle U; Bock HL; Meister W; Clemens R; Kruppenbacher JP
Lancet; 1993 Apr; 341(8851):1028. PubMed ID: 8096914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
